Travecta Therapeutics

ravecta is an emerging biotech company utilizing its novel Blood-Brain Barrier Transport Platform to develop a proprietary pipeline of molecules that treat disorders of the central nervous system. The Travecta Platform leverages their proprietary knowledge of the MFSD2a Transport for the targeted delivery of therapeutic agents to the brain. Their platform and know-how allow us to identify and categorize small molecules for enabling their transport across the blood-brain barrier (BBB). Additionally, Travecta partners with pharmaceutical companies to apply their platform and assist them in overcoming the challenges associated with delivering drugs across the BBB. Travecta’s process allows partners to rapidly confirm BBB transport through feasibility studies that generate in vitro and in vivo transport data of their molecule generated with Travecta’s proprietary models.